13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neuropathy
Neuropathy, or peripheral neuropathy, denotes the impairment or malfunction of peripheral nerves, which form the extensive network outside the brain and spinal cord. These nerves serve as conduits for transmitting signals between the central nervous system and the body, regulating sensations, movements, and organ function. A multitude of factors can precipitate neuropathy, spanning from diabetes and autoimmune conditions to infections like Lyme disease or HIV, traumatic injuries, and exposure to toxins or certain medications. The manifestations of neuropathy vary widely based on the underlying cause and the specific nerves affected, often presenting as numbness, tingling, weakness, or pain in the afflicted regions. In severe instances, neuropathy can culminate in muscle wasting, diminished coordination, and impaired organ functionality. Managing neuropathy pivots on addressing the root cause, where feasible, and alleviating symptoms to bolster quality of life. Treatment modalities may encompass pharmacotherapy to assuage pain and quell inflammation, lifestyle adjustments such as regular exercise and a nutritious diet to manage conditions like diabetes, and physical therapy aimed at bolstering strength, balance, and mobility.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States